Tyra Biosciences has reported initial phase 2 data on dabogratinib in bladd | Tyra Biosciences has reported initial phase 2 ...

Neuro-focused Encoded Therapeutics has bagged a $275 million series F round to support its Dravet syndrome asset and scale up ...

Evommune’s G-protein coupled receptor X2 (MRGPRX2) antagonist has flunked another phase 2 trial, wiping out the biotech’s ...

Kura Oncology has spun out a biotech armed with $50 million in fresh funding to take forward a next-generation diabetes treatment. | Kura Oncology has spun out a biotech armed with $50 million in ...

Luma Group today announced the final close of its inaugural life sciences venture capital fund, totaling $410 million. | Luma Group announced the final close of its inaugural life sciences venture ...

Medtech and testing giant Labcorp has bought out MLM Medical Labs to help grow its geographic footprint for laboratory services.  | Medtech and testing giant Labcorp has bought out MLM Medical Labs to ...

A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the ...

Pharvaris’ deucrictibant has tasted success in a second phase 3 study, strengthening the case for the therapy to treat ...

Boston Scientific has issued another recall, this time for its spinal cord implant used to treat pain. | Boston Scientific ...

Novo Nordisk has given up on two more phase 3 trials of ziltivekimab, further eroding the prospects for a molecule that ...

The recent cyberattack on Boston Scientific is looking more serious than the medtech major first thought, with the company predicting a possible hit to its third-quarter and full-year results. | The ...

Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival (PFS) demonstrated by its OX40 agonist ...